[Federal Register Volume 72, Number 59 (Wednesday, March 28, 2007)]
[Notices]
[Page 14601]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-5674]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Technologies Relating to 
SH2 Domain Binding Inhibitors and Inhibition of Cell Motility and 
Angiogenesis

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the inventions embodied in U.S. 
Patent Application No. 09/937,150, filed March 26, 2002, entitled 
``Phenylalanine Derivatives'' [E-105-1999/0-US-07]; U.S. Patent 
Application No. 10/517,717, filed March 17, 2005, entitled ``SH2 Domain 
Binding Inhibitors'' [E-262-2000/1-US-03]; U.S. Patent Application No. 
10/944,699, filed September 17, 2004, entitled ``SH2 Domain Binding 
Inhibitors'' [E-315-2003/0-US-02]; PCT Patent Application PCT/US05/
35246, filed September 30, 2005, entitled ``A New Approach Toward 
Macrocyclization of Peptides'' [E-327-2004/0-PCT-02]; U.S. Provisional 
Patent Application No. 60/867,307, filed November 27, 2006, entitled 
``Macrocyclic GRB2 SH2 Domain Binding Inhibitors Prepared Using Achiral 
Alkenyl Amines'' [E-305-2006/0-US-01]; U.S. Patent 6,977,241, issued 
December 20, 2005, entitled ``SH2 Domain Binding Inhibitors'' [E-262-
2000/0-US-03]; U.S. Patent 7,132,392, issued November 11, 2006, 
entitled ``Inhibition of Cell Motility and Angiogenesis by Inhibitors 
of the GRB2 SH2 Domain'' [E-265-1999/0-US-07]; to Angion Biomedica 
Corporation, having a place of business in Manhasset, New York. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to cancer and the modulation of 
angiogenesis in inflammatory disease.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before May 
29, 2007 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Adaku Nwachukwu, J.D., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5560; Facsimile: (301) 402-0220; E-
mail: <a href="/cdn-cgi/l/email-protection#1b767a7f6e7a5b767a727735757273357c746d"><span class="__cf_email__" data-cfemail="93fef2f7e6f2d3fef2faffbdfdfafbbdf4fce5">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: These technologies relate to anti-cancer 
drugs that target the inhibition of specific enzymes in certain 
pathways that will interfere with a cell's signal transduction 
processes. The current technologies include specific compounds that 
inhibit GRB2 SH2 domain binding. In addition, the technologies relate 
to how these compounds may inhibit cell motility and angiogenesis.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 16, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-5674 Filed 3-27-07; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>